Advertisement

Monoclonal Antibody-Based Therapy

  • Axel Bex
  • Simon Horenblas
  • Gijsbert C. de Gast

Keywords

Vascular Endothelial Growth Factor Epidermal Growth Factor Receptor Renal Cell Carcinoma Clin Oncol Metastatic Renal Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495–497, 1975.PubMedCrossRefGoogle Scholar
  2. 2.
    Yang JC. Bevacizumab for patients with metastatic renal cancer: An update. Clin Cancer Res 10, 6367s–6370s, 2004.PubMedCrossRefGoogle Scholar
  3. 3.
    Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23(5), 1028–1043, 2005.PubMedCrossRefGoogle Scholar
  4. 4.
    Rini BI. VEGF-targeted therapy in metastatic renal cell carcinoma. The Oncologist 10, 191–197, 2005.PubMedCrossRefGoogle Scholar
  5. 5.
    Srinivasan R, Linehan WM. Targeted for destruction: The molecular basis for development of novel therapeutic strategies in renal cell cancer. J Clin Oncol 23(3), 410–412, 2005.PubMedCrossRefGoogle Scholar
  6. 6.
    Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, et al. Safety, pharmakokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22(15), 3003–3015, 2004.PubMedCrossRefGoogle Scholar
  7. 7.
    Amato RJ. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 2005; 16:7–15.PubMedCrossRefGoogle Scholar
  8. 8.
    Leppert JT, Lam JS, Yu H, Seligson DB, Dong J, Horvath S, et al. Targeting the vascular endothelial growth factor pathway in renal cell carcinoma: A tissue array based analysis. Proc Am Soc Clin Oncol 23, 386s, 2005 (abstract 4536).Google Scholar
  9. 9.
    Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5), 427–434, 2003.PubMedCrossRefGoogle Scholar
  10. 10.
    Hainsworth JD, Sosman JA, Spigel DR, Schwert RC, Carrell DL, Hubbard F, et al. Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). Proc Am Soc Clin Oncol 23, 381, 2004 (abstract 4502).Google Scholar
  11. 11.
    Spigel DR, Hainsworth JD, Sosman J, Raefsky EL, Meluch AA, Edwards D, et al. Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial. Proc Am Soc Clin Oncol 23, 387s, 2005 (abstract 4540).Google Scholar
  12. 12.
    Hainsworth JD, Sosman J, Spigel DR, Patton JF, Thompson DS, Sutton V, et al. Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): A Minnie Pearl Cancer Research Network phase I/II trial. Proc Am Soc Clin Oncol 23, 388s, 2005 (abstract 4542).Google Scholar
  13. 13.
    Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 10, 2584–2586, 2004.PubMedCrossRefGoogle Scholar
  14. 14.
    Holash J, Davis S, Papadopoulos N. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99, 11393–11398, 2002.PubMedCrossRefGoogle Scholar
  15. 15.
    Dupont J, Schwartz L, Koutcher J. Phase I and pharmacokinetic study of VEGF trap administered subcutaneously (sc) to patients with advanced solid malignancies. Proc Am Soc Clin Oncol 23, 197, 2004 (abstract 3009).Google Scholar
  16. 16.
    Motzer RJ, Amato R, Todd M, Hwu WJ, Cohen R, Baselga J, et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21(1), 99–101, 2003.PubMedCrossRefGoogle Scholar
  17. 17.
    Lam JS, Pantuck AJ, Belldegrun A, Figlin R. G250: A carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep 7(2), 109–115, 2005.PubMedCrossRefGoogle Scholar
  18. 18.
    Brouwers AH, Verel I, van Eerd JEM, Visser GWM, Steffens MG, Oosterwijk E, et al. Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma. Cancer Biother Radiopharm 18, 539–547, 2003.PubMedCrossRefGoogle Scholar
  19. 19.
    Wiseman GA, Scott AM, Lee F. Chimeric G250 (cG250) monoclonal antibody phase I dose escalation trial in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 20, 257s, 2001 (abstract 1027).Google Scholar
  20. 20.
    Steffens MG, Boerman OC, De Mulder PH. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131-I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 5(10 Suppl), 3268s–3274s, 1999.PubMedGoogle Scholar
  21. 21.
    Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 90, 985–990, 2004.PubMedCrossRefGoogle Scholar
  22. 22.
    van Spronsen DJ, De Mulder PH. New developments in the treatment of metastatic renal cell carcinoma. Ned Tijdschr Oncol 2(3), 110–116, 2005.Google Scholar
  23. 23.
    Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100(14), 8372–8377, 2003.PubMedCrossRefGoogle Scholar
  24. 24.
    Yang JC, Beck KE, Blansfield JA, Tran KQ, Lowy I, Rosenberg SA. Tumor regression in patients with metastatic renal cancer treated with monoclonal antibody to CTLA4 (MDX-010). Proc Am Soc Clin Oncol , 166s, 2005 (abstract 2501).Google Scholar

Copyright information

© Springer-Verlag London Limited 2008

Authors and Affiliations

  • Axel Bex
  • Simon Horenblas
  • Gijsbert C. de Gast

There are no affiliations available

Personalised recommendations